KDM1A and gastric cancer: In accordance with our results, AGAP2-AS1 was validated to exert oncogenic functions partly by suppressing the transcription of downstream targets by interacting with epigenetic proteins, such as EZH2, LSD1, and CBP (CREB-binding protein), in NSCLC [17], gastric cancer [18] and breast cancer [23].